AAPM Symposium Highlights Evolving Landscape of Chronic Opioid Therapy

March 24, 2011

BALTIMORE, March 24, 2011 –  An educational symposium at the American Academy of Pain Medicine’s Annual Meeting will give attendees the opportunity to learn more about the landscape of chronic opioid therapy.

The dinner symposium, entitled “The Evolving Landscape of Chronic Opioid Therapy and Risk Management” and sponsored by Ameritox, will address changes in the treatment landscape of chronic opioid therapy. The event will be held Saturday, March 26 at 5:30 p.m. in Woodrow Wilson Ballroom A at the Gaylord National Hotel and Convention Center in National Harbor, Md.

The symposium includes speakers with expertise in both pain and risk management. Speakers include Steve Passik, PhD, an Associate Attending Psychologist at Memorial Sloan-Kettering Cancer Center in New York; Heide Bajnrauh, a public policy advisor for Patton Boggs, LLP, a leading public policy firm based out of Washington, D.C.; Michael Larson, PhD, Assistant Director of Clinical Research for Northern Division at Wisconsin’s Marshfield Clinic; and Ami Buikema, MPH, senior researcher at i3 Innovus, along with Harry Leider, MD, MBA, chief medical officer of Ameritox.

The program’s speakers will address evolving state regulations and treatment guidelines for managing patients with chronic pain, recent changes in reimbursement for different types of office-based urine drug testing, new tools to help physicians assess pain control while reducing opioid misuse, abuse, and diversion and the impact of non-adherence with opioid therapy on healthcare costs in the chronic opioid therapy population.

Information about the symposium, including registration instructions, can be found at: http://symposiareg.org/aapm/ws_symposia/symposia_pub_view.php?symposia_id=48

About Ameritox: Ameritox is the nation’s leader in pain medication monitoring solutions, offering specialized laboratory testing and reporting services. Ameritox’s expertise and innovative science provides physicians with insights and support to enhance and optimize the care of chronic pain patients. Ameritox offers Rx GuardianSM, the most thorough and personalized lab service available and the only pain medication testing program with a proprietary methodology to help physicians assess whether patients are taking their pain medication correctly. Medication monitoring helps physicians make more informed clinical decisions and manage the risks and complexities associated with prescribing pain medications. Ameritox is headquartered in Baltimore, MD with laboratory facilities in Midland, TX and Greensboro, NC.
To learn more about urine drug monitoring solutions, visit Ameritox.com.

© 2011, Ameritox, Ltd. All rights reserved. AMERITOX, the AMERITOX logos, PAIN MEDICATION MONITORING SOLUTIONS, AMERITOX MEDICATION MONITORING SOLUTIONS, Rx GUARDIAN AUTOREMINDER, Rx GUARDIAN and PROTECT YOUR PATIENTS, PROTECT YOUR PRACTICE, are trademarks of Ameritox. All other trademarks are the claimed trademarks of others.